MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$170,236K
EPS
-$131.45
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
17,957
3,357*
2,536
2,533
General and administrative expenses
19,713
3,784*
2,315
2,673
Long-lived asset impairment
-
0*
-
-
Acquired in-process research and development
132,957
-
-
-
Total operating expenses
170,627
7,140
4,851
5,206
Loss from operations
-170,627
-7,140*
-4,851
-5,206
Interest income, net
392
324*
289
321
Interest expense
-
8*
6
10
Loss on asset disposal
-
-
-1
-40
Other (expense) income, net
-1
-2*
0
-1
Net loss
-170,236
-6,827
-4,569
-4,936
Net loss attributable to common stockholders
-
-6,827
-
-
Basic EPS
-131.45
-5.418
-3.62
-3.91
Diluted EPS
-131.45
-5.418
-3.62
-3.91
Basic Average Shares
1,295,052
1,260,159
1,261,290
1,260,867
Diluted Average Shares
1,295,052
1,260,159
1,261,290
1,260,867
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$170,236K
Interest income, net
$392K
Loss from operations
-$170,627K
Other (expense)
income, net
-$1K
Total operating
expenses
$170,627K
Acquired in-process
research and development
$132,957K
General and
administrative expenses
$19,713K
Research and development
$17,957K
Buy us a coffee
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)